Dr. Qiong Wang is an accomplished R&D executive with over 20 years of experience advancing innovation in immuno-oncology, cell therapy, and translational research across academia, global pharma, and biotech. She currently serves as Chief Scientific Officer at a startup focused on AI-enabled target discovery from the dark genome for cancer immunotherapy.

Dr. Wang began her career at the Surgery Branch, National Cancer Institute (NCI), where her discoveries led to the development of CD70-directed CAR-T therapies and the first TCRs targeting KRAS G12V and G12D mutations, several of which progressed to clinical trials and licensing deals with biopharma. She has since held R&D leadership roles with increasing scope at MedImmune, AstraZeneca, Legend Biotech, and Matterhorn Biosciences. At Legend Biotech, as the US R&D site head, she established and led R&D operations across the US and Ireland, launched next-generation CAR-T and TCR-T programs, and played a pivotal role in the company’s pre-IPO and IPO process. At Matterhorn Biosciences, she served as Chief Scientific Officer, overseeing R&D operations across Switzerland and the US.

Dr. Wang brings deep scientific insight and strategic perspective to her advisory role, with expertise spanning target discovery, TCR/CAR development, and AI-driven approaches to next-generation immunotherapies.